Although several studies have demonstrated that CD133 protein expression could be increased in a wide range of human cell malignancies, including metastatic lesions or tumor recurrent for cancer patients, it could also be over-expressed in malignancy (4,9) or cancer stem cell derived from melanoma samples (5). This evidence concerns the gene PROM1 and cancer.